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Camptothecin (Cpt) and related chemotherapeutic drugs induce formation of DNA topoisomerase I (top1) covalent or 
cleavage complexes (top1ccs) that block leading-strand DNA synthesis and elicit DNA Double Stranded Breaks (DSB) 
during S phase. the Fanconi Anemia (FA) pathway is implicated in tolerance of Cpt-induced DNA damage yet the 
mechanism of FA pathway activation by top1 poisons has not been studied. We show here that the FA core complex 
protein FANCA and monoubiquitinated FANCD2 (an effector of the FA pathway) are rapidly mobilized to chromatin in 
response to Cpt treatment in several human cancer cell lines and untransformed primary human dermal fibroblasts. 
FANCD2 depletion using siRNA leads to impaired recovery from Cpt-induced inhibition or DNA synthesis, persistence 
of γH2AX (a DSB marker) and reduced cell survival following Cpt treatment. the e3 ubiquitin ligase Rad18 is necessary 
for Cpt-induced recruitment of FANCA and FANCD2 to chromatin. Moreover, Rad18-depletion recapitulates the DNA 
synthesis and survival defects of FANCD2-deficiency in Cpt-treated cells. It is well-established that Rad18 promotes 
FA pathway activation and DNA damage tolerance in response to bulky DNA lesions via a mechanism involving pCNA 
monoubiquitination. In contrast, pCNA monoubiquitination is not involved in Rad18-mediated FA pathway activation or 
cell survival following acquisition of Cpt-induced DSB. Moreover, while Rad18 is implicated in recombinational repair of 
DSB via an e3 ligase-independent mechanism, we demonstrate that Rad18 e3 ligase activity is essential for appropriate FA 
pathway activation and DNA damage tolerance after Cpt treatment. taken together, our results define a novel pathway 
of Rad18-dependent DSB repair that is dissociable from known Rad18-mediated DNA repair mechanisms based on its 
independence from pCNA ubiquitination and requirement for e3 ligase activity.
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with TLS, ensuring appropriate processing of bulky DNA lesions. 
FA is a cancer predisposition syndrome in humans. To date, at 
least 13 complementation groups of FA have been identified (des-
ignated ‘FANC’ A-M). The FA proteins (FANCs) are thought to 
work cooperatively in a common pathway to repair interstrand 
crosslinks.28 The eight-protein core complex (complementation 
groups, A–C, E–G, L and M) acts as an E3 ligase to monou-
biquitinate FANCD2 and FANCI in response to acquisition 
of DNA damage and replication stress during S phase. Upon 
monoubiquitination, the FANCD2/I complex is recruited to 
chromatin and promotes DNA repair.29-31 The remaining three 
FA proteins are breast cancer susceptibility related genes (BRCA) 
FANCD1/ BRCA2, FANCJ, FANCN, which are thought to func-
tion downstream of FANCD2/I.28,32-35 Although the FA pathway 
is widely hypothesized to participate in DNA repair and main-
tenance of genomic stability, its precise biochemical role(s) are 
unknown. The FA pathway is implicated in the repair of DNA 
interstrand crosslinks and fork-stalling lesions.31,32 However, very 
little is known regarding roles of the FA pathway in processing 
and repair of Top1 inhibitor-induced DNA lesions. Since Top1 
inhibitors induce DNA replication-dependent lesions, it is likely 
that the FA pathway participates in processing and repair of Top1-
inhibitor-induced DNA damage. Recently, Elledge and colleagues 
reported that FANCD2, FANCI and FANCJ-deficient cells are 
hypersensitive to CPT yet display only moderate IR-sensitivity.36
Covalent trapping of Top1 on DNA by CPT (Top1ccs) induces 
aberrant DNA structures and lethal DNA lesions, such as accu-
mulation of positive supercoils and DSB.8,10,37 Several DNA repair 
proteins that interact either directly or indirectly with FANCs are 
required for tolerance of Top1-mediated DNA damage. Indeed, 
deficiency or mutations in multiple components of the FA path-
way (FANCB, FANCM, FANCJ, FANCD1, FANCD2 and 
FANCI) leads to CPT sensitivity.36,38-40 However, little is known 
regarding activation mechanisms of the FA pathway and its role 
in response to Top1-inhibitors-induced DNA damage.
Because we and others recently showed that Rad18 contributes 
to FA pathway activation in response to bulky DNA adducts,27 
it was of interest to test the potential role (if any) of Rad18 in 
CPT-induced FA pathway activation. In response to bulky DNA 
lesions, Rad18-dependent FA pathway activation is mediated via 
PCNA ubiquitylation and requires Polη.27 We show here that in 
contrast with bulky DNA lesions, CPT does not induce PCNA 
ubiquitination. Surprisingly, however, we demonstrate that 
Rad18-mediated FA pathway activation by CPT and tolerance of 
CPT-induced damage are dependent on Rad18 E3 ubiquitin ligase 
activity. This work defines a new role for Rad18 in DNA repair, 
which is dissociable from its known functions in TLS and HR 
(which require PCNA ubiquitination and are E3 ligase-indepen-
dent respectively). Moreover, this study indicates the existence of 
Rad18 substrates other than PCNA that are involved in FA path-
way activation and tolerance of CPT-induced DNA lesions.
Results
CPT activates the FA pathway. Several reports implicate the FA 
pathway in tolerance and repair of DNA damage due to CPT and 
Introduction
DNA Topoisomerase I (Top1) plays a critical role in mainte-
nance of genome integrity by resolving topological strain during 
vital cellular processes such as DNA replication, transcription 
and chromatin remodeling.1-5 Top1 relaxes DNA supercoils by 
generating and quickly resealing a single-stranded break in the 
duplex DNA.6 Top1 is also a molecular target of the anti-can-
cer drug camptothecin (CPT) and related chemotherapeutics 
(including topotecan, irenotecan). CPT and related drugs revers-
ibly trap Top1-DNA covalent or cleavage complexes (Top1ccs) 
by intercalating into the Top1-DNA nick and prevent the scis-
sile strand’s religation.7-10 Stabilization of Top1-DNA complexes 
by CPT induces aberrant DNA structures and accumulation of 
positive supercoils, which, following encounters with the DNA 
replication and transcription machinery, may lead to lethal 
DNA double-strand breaks (DSB).9-11 However, the mechanisms 
underlying the repair of CPT-induced lesions are not well under-
stood. Studies in yeast and mammalian cells have identified mul-
tiple DNA damage signaling and repair pathways that respond 
to CPT, including those involved in DNA replication and cel-
lular responses to single and double-stranded DNA breaks.12-16 
Nevertheless, the molecular networks that integrate DNA repli-
cation, DNA repair in CPT-treated cells are poorly defined.
Rad18 is an E3 ubiquitin ligase whose role in DNA damage 
tolerance is best understood for a post-replication repair mecha-
nism termed “Trans-lesion Synthesis” (TLS).17-19 In response to 
replication fork-stalling, bulky DNA lesions such as cyclobu-
tane pyrimidine dimers (CPD) or Benzo[a]pyrene di-hydro-diol 
epoxide (BPDE) adducts, Rad18 monoubiquitinates PCNA. 
Monoubiquitinated PCNA, in turn, promotes the recruitment 
of specialized “Y-family” DNA polymerases Polη, Polκ, Polι and 
REV1 to sites of DNA damage, thereby facilitating replication of 
damaged DNA templates.17-21 Recent work from several laborato-
ries indicates that recruitment of TLS polymerases to damaged 
DNA is not restricted to S phase.22 Therefore, Y-family poly-
merase activities may be involved in replication fork-independent 
repair and processing of adducted DNA. In many instances, 
Rad18-deficiency confers hypersensitivity to bulky DNA lesions, 
presumably due to its role in promoting lesion bypass by the 
Y-family DNA polymerases.
Rad18-deficient cells are also sensitive to DSB-inducing 
agents, such as ionizing radiation (IR) and CPT.23-25 Work from 
the Chen laboratory defined a novel role for Rad18 in recruit-
ing Rad51 and its paralogs to DSB, thereby promoting DNA 
repair via homologous recombination (HR).23,26 Interestingly, 
Rad18 E3 ubiquitin ligase activity (which is required for PCNA 
monoubiquitination and efficient TLS) is dispensable for Rad18-
mediated Rad51 recruitment and resistance to DSB-inducing 
agents.23 Thus, Rad18-mediated TLS and HR mechanisms are 
dissociable via their dependence on E3 ubiquitin ligase activity.23
Our recent studies have shown that Rad18 E3 ubiquitin ligase 
activity and PCNA ubiquitination are required for appropriate 
activation of the Fanconi Anemia (FA) pathway in response to 
bulky adducts induced by BPDE and UV irradiation.27 Thus, 
Rad18 provides a mechanism for coupling FA pathway activation 
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(colon carcinoma) and non-transformed Human Dermal 
Fibroblasts (HDF). Surprisingly, FANCD2 monoubiquitination 
was compromised as a result of Rad18-depletion in several cell 
lines, including H1299, A549 and Human Dermal Fibroblasts 
(Fig. 2A–C). CPT-induced FANCD2 ubiquitination was also 
attenuated in RAD18-/- HCT116 cells compared with isogenic 
RAD18+/+ parental HCT116 cells (Fig. 2D). Therefore, FA path-
way activation in response to CPT is Rad18-dependent. Note 
that we typically observed slight decrease in Rad18 levels fol-
lowing FANCD2-depletion (see for example Figs. 2B and 3B). 
In a recent study, we reported that FANCD2 and Rad18 may 
be co-immunoprecipitated as a complex.45 Whether Rad18 and 
FANCD2 associate directly or via other proteins is not known 
and is beyond the focus of this study. However, it is very common 
for DNA repair proteins to stabilize their binding partners, and 
this provides a plausible explanation for the effect of FANCD2-
depletion on Rad18 levels.
In clonogenic survival assays Rad18-depleted H1299 cells 
were sensitized to CPT-induced killing relative to control Rad18-
replete cultures (Fig. 3A). CPT-sensitivity following Rad18 abla-
tion was also observed in experiments using A549 cells (data not 
shown). Co-depletion of Rad18 and FANCD2 did not have a sig-
nificant additive effect on sensitivity to killing by CPT (Fig. 3A). 
Nevertheless, our partial co-depletion experiments (Fig. 3A) sug-
gest that Rad18 and FANCD2 function in a common pathway, 
or at least a partially overlapping pathway to confer tolerance of 
CPT-induced lesions.
We considered the formal possibility that Rad18 or FANCD2 
status affects acquisition of Top1ccs following CPT treatment. 
Therefore, we used in vivo complex Enzyme (ICE) bioassays to 
determine the effect of Rad18 and FANCD2 status on levels of 
CPT-induced Top1ccs. Lysates from control and CPT-treated 
cells were fractionated by centrifugation on CsCl gradients. 
The individual fractions were dot-blotted onto nitrocellulose 
filters and probed with a Top1 antibody. For each experimen-
tal sample from CPT-treated cells (but not control cultures), 
Fraction 1 (enriched in genomic DNA) showed increased reac-
tivity with anti-Top1 antibodies (Fig. 3C), indicating the pres-
ence of CPT-induced Top1ccs. We did not observe significant 
changes in spontaneous or CPT-induced Top1ccs formation as 
a result of Rad18- or FANCD2 depletion. Therefore, Rad18 and 
FANCD2 do not influence formation of CPT-induced Top1ccs, 
but affect distal events in the response to CPT-induced DNA 
damage. Taken together, these data suggest that Rad18 contrib-
utes to CPT-induced FA pathway activation and tolerance of 
CPT-induced DNA damage.
Rad18-deficient cells are defective in repair and recovery of 
CPT induced DNA damage. CPT-stabilized Top1ccs are known 
to interfere with ongoing DNA synthesis, potentially leading to 
DSB and replication fork collapse.9 We determined the effect of 
Rad18 and FANCD2 status on accumulation of γH2AX foci 
(a marker of ATM and ATR signaling) at different times after 
CPT treatment. As shown in Figure 4A, 40.3% (±9.2) of the 
control (siCon-transfected) cells contained γH2AX foci one hour 
after CPT treatment. At this time point, FANCD2- and Rad18-
depleted cells accumulated slightly higher levels of γH2AX foci 
other Top1 inhibitors.39,41 However, mechanisms of FA pathway 
activation in response to CPT have not been studied. To deter-
mine whether the FA pathway is activated in response to CPT, we 
treated H1299 lung carcinoma cells with 100 nM CPT for 1 hour 
and then examined the sub-cellular distribution and chromatin-
binding of FANCD2 using immunofluorescence (IF) microscopy 
and immunoblotting (IB) respectively. As shown in Figure 1A 
(40x magnification) and 1B (100x magnification), CPT treat-
ment induced an increase in the number of FANCD2 nuclear 
foci (likely corresponding to sites of DNA repair) in H1299 cells. 
Camptothecins are well established S phase-specific chemothera-
peutic agents, and most of their cytotoxicity at sub-micromolar 
concentrations is dependent on DNA replication.9 Since we have 
used relatively low doses of CPT in this study (100 nM), the 
FANCD2 nuclear foci we observed in CPT-treated cells likely 
correspond to stalled/collapsed replication forks. Indeed, the 
FANCD2 foci co-localized with PCNA (Fig. 1C) and there-
fore represent sites of DNA replication. Since CPT induces DSB 
at sites of DNA replication, we conclude that the FANCD2 
foci represent replication-induced DSB. CPT treatment also 
induced an increase in the levels of chromatin-bound FANCD2, 
the monoubiquitinated species of FANCD242 in H1299 cells 
(Fig. 1D) and in FANCD2-complemented PD-20 cells (Fig. 1E). 
Supplemental Figure 1 also demonstrates that the CPT-induced 
chromatin-associated FANCD2 corresponds to the electropho-
retically retarded (monoubiquitinated) species.
To determine the role of the FA core complex in FA path-
way activation by CPT, we compared CPT-induced FANCD2 
ubiquitination in FANCA (-) GM6914 cells and an isogenic 
FANCA (+) cell line complemented with a functional FANCA 
cDNA. As shown in Figure 1F, CPT treatment induced chro-
matin-binding of monoubiquitinated FANCD2 in FANCA (+) 
cells. However, even though levels of soluble FANCD2 were 
comparable in FANCA (+) and FANCA (-) cells, CPT did not 
induce chromatin association of FANCD2 in the absence of 
FANCA. In siRNA experiments using H1299 cells, we achieved 
partial FANCA-depletion, which resulted in attenuation of CPT-
induced FANCD2 ubiquitination (Fig. 1G). We infer that CPT-
induced FANCD2 ubiquitination is FA core complex-dependent. 
Consistent with previous reports using other cell lines,39 
FANCD2-depleted H1299 cells exhibited increased sensitivity 
to CPT when compared with control siRNA-transfected cells 
(Fig. 1H). Therefore, CPT induces FA core complex-mediated 
FANCD2 monoubiquitination. Moreover, FANCD2 is necessary 
for tolerance of CPT-induced DNA damage.
Rad18 mediates CPT-induced FA pathway activation. 
Rad18 contributes to FA pathway activation by various bulky 
DNA lesions, including BPDE, CPD and cis-Pt adducts.27,43 In 
those studies, the Rad18-dependent component of FANCD2 
ubiquitination was mediated via PCNA monoubiquitination. 
Because CPT does not induce detectable PCNA monoubiquiti-
nation,44 we predicted that CPT-induced FANCD2 monoubiq-
uitination would be Rad18-independent. Therefore we tested the 
effect of Rad18-deficiency on CPT-induced FA pathway activa-
tion in several cell lines, including H1299 (p53-deficient lung 
carcinoma), A549 (p53-expressing lung carcinoma), HCT 116 
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Figure 1. For figure legend, see page 1629.
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chromatin-binding of Rad51 in control cells. The increased chro-
matin association of FANCD2 and Rad51 persisted for at least 
6 hours after CPT washout. In Rad18-depleted cells chromatin-
loading of FANCD2 and Rad51 was attenuated. Interestingly, 
chromatin binding of Rad51 was also affected by FANCD2 
depletion, most likely because of the proposed role of FANCD2 
in promoting HR.47,48
Consistent with failure of Rad18- and FANCD2-depleted 
cells to resume DNA synthesis, chromatin levels of replication 
markers such as Cdc45 and PCNA and Mcm7 also decreased 
more persistently after CPT treatment in Rad18- or FANCD2-
ablated cells relative to siCon-transfected cultures (Fig. 4D). The 
decrease in chromatin-binding of Cdc45 concomitant with inhi-
bition of DNA synthesis was of the same magnitude that we and 
others have previously observed following induction of S-phase 
checkpoint signaling.49,50
We consistently observed an increase in chromatin loading 
of replication factors after CPT washout in the FANCD2 and 
Rad18-replete (siCon) cultures. Blow and colleagues have shown 
that replication stress can lead to firing of otherwise dormant ori-
gins.51,52 Therefore, the increased replication factor loading that 
we observe concomitant with recovery from replicative arrest is 
potentially consistent with published mechanisms of S-phase 
DNA damage tolerance. Taken together, our results suggest that 
persistent CPT-induced replicative arrest in Rad18-depleted cells 
is associated with defective activation of FANCD2 and HR, lead-
ing to reduced processing of CPT induced DNA lesions.
Rnf8 is required for FA pathway activation by CPT. Rad18 
is recruited to stalled replication forks due to recognition of RPA-
coated DNA structures generated by uncoupling of replicative 
helicase and polymerase activities.25,53 In contrast, Rad18 recruit-
ment to DSB is dependent on the E3 ligase RNF8 and ubiq-
uitination of histone H2A.23 Because CPT-induced lesions do 
not cause replicative helicase-polymerase uncoupling or induce 
PCNA ubiquitination, we predicted that Rad18 activation by 
CPT would be RNF8-dependent. Therefore, we tested the effects 
of RNF8-depletion on CPT-induced FA pathway activation. As 
shown in Figure 5, CPT-induced FANCD2 ubiquitination and 
levels of Rad18 on chromatin were attenuated in Rnf8-depleted 
when compared to siCon-transfected cultures (48.9 ± 7.5% and 
57.6 ± 7.1 cells contained nuclear γH2AX foci in siFANCD2 
and siRad18-transfected cultures, respectively). Six hours after 
CPT washout, the number of cells containing γH2AX foci 
declined to 20.1% (±5.3) in the siCon-transfected cultures, 
indicating that approximately half of the CPT-induced DNA 
damage was repaired (Fig. 4A). Interestingly, however, levels of 
γH2AX foci remained relatively high 6 hr after CPT washout 
in the siFANCD2 and siRad18-transfected cells (36.7% ± 3.8 
and 56.1% ± 6.4 cells retained γH2AX foci in FANCD2- and 
Rad18-depleted cultures, respectively). The persistence of 
γH2AX foci in Rad18- and FANCD2-depleted cells is an indi-
cation of a residual DNA damage signaling and suggests a role 
for Rad18 and the FA pathway in processing and/or repair of 
CPT-induced DSBs.
Failure to repair replication-associated DNA damage often 
results in more persistent inhibition of DNA synthesis following 
genotoxin exposure.20,46 Therefore, we determined the effects of 
CPT treatment on rates of DNA synthesis in control and Rad18- 
and FANCD2-depleted cells. As shown in Figure 4B, in con-
trol (siCon-transfected) cultures, DNA synthesis was transiently 
inhibited by 54.4% 1 hr after CPT treatment. However, DNA 
synthesis recovered and normal rates of replication were resumed 
8 hr after CPT treatment in the control cultures. In Rad18- 
and FANCD2-depleted cells, DNA synthesis was more sensi-
tive to inhibition by CPT (49.8 and 30.5% inhibition 1 hr after 
CPT). Moreover, rates of DNA synthesis were inhibited more 
persistently following CPT treatment in Rad18- and FANCD2-
depleted cells and failed to resume control levels within the time 
frame of this experiment (Fig. 4B). Whether resumption of DNA 
synthesis occurs due to repriming, dormant origin firing or restart 
via other mechanisms cannot be inferred from these experiments. 
Nevertheless, our results demonstrate that FANCD2 and Rad18 
are required for maintenance of DNA replication in CPT-treated 
cells.
In parallel we also assessed the kinetics of FANCD2 and 
Rad51 chromatin loading in CPT-treated cells. As shown in 
Figure 4C, CPT treatment induced a ~2-fold increase in the 
chromatin-association of FANCD2 and ~2–5-fold increases in 
Figure 1 (See opposite page). Cpt activates the FA pathway. (A) exponentially growing H1299 cells in chamber slides were treated with 100 nM Cpt 
(or DMSo for controls). After 1 hr, cells were fixed with 4% formaldehyde, permeabilized to remove soluble proteins, stained with α-FANCD2 antibod-
ies and visualized by using immunofluorescence microscopy at 40x magnification, as described under Materials and Methods. (B) A representative cell 
from a Cpt-treated culture showing FANCD2 nuclear foci (shown at 100x magnification). (C) H1299 Cells were treated with Cpt and fixed as described 
for (A) above. Fixed cells were co-stained with α-FANCD2 and α-pCNA antibodies and visualized by using immunofluorescence microscopy at 100x 
magnification. the representative cells shown have patterns of pCNA and FANCD2 foci suggestive of early (left) and late (right) DNA replication. (D) 
In parallel with the experiment described in (A), exponentially growing H1299 cells were treated with 100 nM Cpt (or DMSo for controls). After 1 hr, 
chromatin was extracted from the cells and analyzed by SDS-pAGe and immunoblotting with the indicated antibodies. (e) exponentially growing 
pD20 FANCD2 (-) cells and isogenic FANCD2 (+) cells expressing stably reconstituted wild-type FANCD2 were treated with 100 nM Cpt for 1 hr. Chro-
matin and soluble extracts from the cells were resolved by SDS-pAGe and analyzed by immunoblotting with the indicated antibodies. (F) exponen-
tially growing GM6914 FANCA (-) fibroblasts or isogenic FANCA (+) cells expressing stably reconstituted wild-type FANCA were treated with Cpt and 
analyzed as described for (e) above. (G) Replicate cultures of exponentially growing H1299 cells were transfected with siRNAs targeting FANCD2, FANCI 
and FANCA (or with non-targeting siRNA for controls) as described under experimental procedures. the resulting cells were treated with Cpt and 
analyzed for expression of various FANCs as described under Materials and Methods. (H) H1299 cells were transfected with siFANCD2 or non-targeting 
siCon RNAs as described under Materials and Methods. Forty-eight hr post-transfection, siFANCD2 and siCon cells were seeded in 6-well plates and 
treated with the indicated concentrations of Cpt in triplicate for 16 hours. After washout, cells were given fresh medium and allowed to form colonies. 
After 7–10 days, colonies containing >50 cells were enumerated. the graph shows the result of a representative experiment. each data point repre-
sents the mean of triplicate determinations and the error bars represent standard deviations.
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cells. In agreement with the studies of Chen and colleagues, 
Rnf8-depletion also reduced CPT-induced chromatin-associ-
ation of Rad51.
CPT-induced FA pathway activation requires Rad18 E3 
ligase activity. Rad18-mediated TLS is dependent on 
PCNA-directed E3 ubiquitin ligase activity,18 whereas Rad18-
mediated HR is E3 ligase-independent.23 We asked whether 
Rad18 E3 ligase activity is required for CPT-induced FA 
pathway activation and tolerance of CPT-induced lesions. 
Therefore, we depleted endogenous Rad18 using siRNAs 
targeting the 3'-UTR region of the RAD18 transcript. The 
resulting cells were complemented with expression vectors 
encoding siRNA-resistant Wild-Type (WT) Rad18 or an 
E3 ubiquitin ligase-defective Rad18 harboring a C28F point 
mutation. Control and Rad18-complemented cells were 
assessed for CPT-induced chromatin association of FANCD2, 
Rad51 (using immunoblotting) and CPT sensitivity (using 
clonogenic survival assays).
As shown in Figure 6A, CPT-induced FANCD2 ubiquiti-
nation was compromised in Rad18-depleted cells. Expression 
of Rad18 (WT) but not Rad18 (C28F) complemented the 
defective FANCD2 chromatin binding of Rad18-depleted 
cells.
As expected from a previous report in reference 23, both 
WT Rad18 and Rad18-C28F corrected the defective chroma-
tin loading of Rad51. Interestingly, in colony survival assays 
WT Rad18 but not the E3 ligase-inactive Rad18 (C28F) 
mutant fully complemented the CPT sensitivity resulting 
from depletion of endogenous Rad18 (Fig. 6B). Therefore 
Rad18 (C28F) supports chromatin loading of Rad51 and 
normal HR activity23 but cannot mediate CPT-induced 
FANCD2 ubiquitination or confer CPT-tolerance.
We note that the levels of ectopically expressed Rad18 
achieved by transient transfection exceed physiological Rad18 
levels and led to DNA damage-independent PCNA monou-
biquitination. Many Rad18-dependent responses to DNA 
damage are mediated via PCNA monoubiquitination. We con-
sidered the possibility that Rad18-dependent PCNA monou-
biquitination was involved in FA pathway activation tolerance 
of CPT-induced DNA damage under our experimental condi-
tions. However, although PCNA was highly ubiquitinated in 
Rad18 (WT)-transfected cells (even without genotoxin treat-
ment), this level of PCNA ubiquitination alone was clearly 
insufficient to induce FANCD2 monoubiquitination in the 
absence of CPT treatment (Fig. 4A). Moreover, we did not 
detect PCNA ubiquitination in response to CPT, even though 
the doses of CPT used here induced similar levels of Chk1 
phosphorylation to that elicited by 20 J/m2 of UVC (a fluence 
Figure 2. Cpt-induced FANCD2 ubiquitination is Rad18-mediated. 
Replicate plates of H1299 cells (A), A549 cells (B), HCt116 cells (C) 
and HDF (D) differing with respect to Rad18 status were treated with 
Cpt for 1 hr, separated to give soluble and chromatin fractions and 
analyzed using SDS-pAGe and immunoblotting with antibodies 
against the indicated proteins. Note that the commercially available 
Rad18 antibody detects a minor non-specific band of approximately 
the same size as human Rad18 (evident in the Rad18-/- cell extracts).
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monoubiquitinated FANCD2 promotes DSB repair via homolo-
gous recombination.47 More recent studies suggest that the FA 
pathway plays a role in resecting dsDNA ends, thereby directing 
repair away from abortive NHEJ and toward HR.48
Consistent with a role for the FA pathway in promoting HR, 
FA cells show sensitivity to CPT (Nomura et al. and this study) 
and studies using replication-competent Xenopus egg extracts 
have suggested a requirement for FANCD2 in replication restart 
following CPT-induced fork collapse.41 However, mechanisms of 
FA pathway activation and integration of the FA pathway with 
other DNA replication and repair processes have not been studied.
that elicits both Chk1 phosphorylation and PCNA monoubiqui-
tination, as shown in Fig. 6C). These results are fully consistent 
with the observations of Niimi et al. who showed that CPT does 
not induce PCNA monoubiquitination, and that PCNA modi-
fication at K164 is necessary for tolerance of UV-induced DNA 
damage but dispensable for tolerance of CPT-induced lesions. 
Taken together, these results identify a novel Rad18-mediated 
mechanism for processing and/or repair of CPT-induced DNA 
damage. Moreover, because cellular responses to CPT are PCNA 
ubiquitination-independent,44 we infer that alternative targets of 
Rad18 E3 ligase activity mediate repair of CPT-induced lesions.
Rad18 status affects chromatin loading of FA core com-
plex proteins but not USP1 expression. DNA damage-induced 
FANCD2 monoubiquitination is promoted by the FA core com-
plex (which contains the FANCD2-directed E3 ligase FANCL) 
and is antagonized by the de-ubiquitinating (DUB) enzyme 
USP1, which is degraded in response to genotoxins.54 We investi-
gated whether Rad18-dependent FANCD2 ubiquitination is due 
to increased core complex activation or decreased USP1 levels.
As shown in Figure 7, levels of USP1 were unaffected by CPT 
treatment in control (Rad18-replete) cultures. Therefore, in con-
trast with certain other genotoxins,54 FANCD2 ubiquitination in 
response to low doses of CPT is not a result of USP1 degradation. 
Moreover, USP1 levels were not affected by Rad18-depletion. We 
conclude that changes in USP1 levels do not account for CPT-
induced and Rad18-mediated FA pathway activation.
In both control and Rad18-depleted cells, chromatin bind-
ing of the FA core complex components FANCA and FANCL 
increased in response to CPT treatment. Moreover, levels of 
chromatin-associated FANCA and FANCL were reduced in 
Rad18-depleted cells (Figs. 2A–D and 6A), both basally and fol-
lowing CPT treatment. Therefore, our results suggest that Rad18 
regulate FANCD2 monoubiquitination via a mechanism involv-
ing increased targeting of the FA core complex to chromatin at 
sites of CPT-induced lesions.
Discussion
Top1 poisons such as CPT target S-phase cells,55 causing DNA 
replication-associated DNA damage. Thus, Top1ccs are con-
verted to DSB via a “replication run-off” mechanism, whereby 
the leading strand is replicated only up to the last nucleotide 
flanking the 5' end of the TOP1cc and terminates in a DSB.56 
Genetic alterations in DSB-inducible checkpoint signaling path-
ways (e.g., ATM, CHK2) and DSB-specific DNA repair mecha-
nisms (e.g., NBS1, Rad51C) sensitize mammalian cells to Top1 
poisons,9 further consistent with a DSB-mediated mechanism for 
killing of cells in response to Top1 inhibitors.
While the FA pathway has been studied most extensively 
in the context of DNA interstrand crosslink repair, FANCs 
have also been implicated in processing and repair of DSB. In 
eukaryotic cells, two main pathways exist for repair of DSB: 
Non-Homologous End Joining (NHEJ) and Homology-
Directed Repair (HDR). Studies with cells from mutant Fancd2-
/- mice suggested an NHEJ-independent role for Fancd2 in 
repair of IR-induced DSB.57 Jasin and colleagues showed that 
Figure 3. Rad18-depletion confers Cpt-sensitivity. (A) H1299 cells were 
transfected individually or in combination with siRNAs against Rad18 
and FANCD2 (or with non-targetting siCon RNA). the resulting cultures 
were seeded in 6-well plates and treated with the indicated concentra-
tions of Cpt in triplicate for 16 hours. After washout, cells were given 
fresh medium and allowed to form colonies. After 7–10 days, colonies 
containing >50 cells were enumerated. the graph shows the result 
of a representative experiment. each data point represents the mean 
of triplicate determinations and the error bars represent standard 
deviations. (B) In parallel with the experiment described in (A) above, 
siRNA-transfected cells were analyzed by SDS-pAGe and immunoblot-
ting of whole cell extracts to confirm changes in FANCD2 and Rad18 
expression. (C) In parallel with experiments described in (A and B) 
above, siCon-, siFANCD2- and siRad18-transfected cells were lysed 
in 1% sarkosyl following Cpt treatment. Bottom four fractions of the 
CsCl gradient fractionated DNA were immobilized on membranes and 
top1-DNA covalent or cleavage complexes were detected with α-top1 
antibody as described under Materials and Methods.
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cells. We and others have previously shown that FA pathway acti-
vation in response to bulky DNA lesions is Rad18-dependent.27,43 
The mechanism of FANCD2 ubiquitination in response to bulky 
DNA lesions (such as BPDE adducts and CPD) is indirect and 
We show here that efficient CPT-induced FANCD2 activation 
requires the Rad18 E3 ubiquitin ligase. Consistent with a role for 
Rad18 in CPT-induced FA pathway activation, we show that both 
FANCD2 and Rad18 are required for survival of CPT-treated 
Figure 4. Recovery from Cpt-induced DNA damage is compromised in Rad18- and FANCD2-deficient cells. (A) Duplicate cultures of A549 cells growing 
in chamber slides were transfected with siRNAs targeting Rad18 and FANCD2 (or non-targeting RNA for control). For each replicate culture, one well 
was treated with 1 μM Cpt for 1 hr and fixed immediately. Cells in the other duplicate well were washed extensively to remove Cpt and were then 
returned to the incubator and allowed to recover in drug-free medium for 6 hr before fixing. Fixed cells were stained with γH2AX antibodies and 
mounted in DApI. In a blinded analysis, ten fields (each containing 20–40 cells) were examined. Cells containing >5 γH2AX foci were scored “positive.” 
For each field the percentage of γH2AX-positive cells was calculated. each data point represents the mean percentage of γH2AX-positive cells from 
ten fields and the error bars represent standard deviations. (B) In parallel with the experiment described in (A), A549 cells transfected with siRad18, si-
FANCD2 or siCon were plated in 24-well culture dishes. the resulting cultures were treated with 500 nM Cpt (or were left untreated for controls). Rates 
of DNA synthesis were determined by measuring [3H]-thymidine incorporation for 1 hr immediately prior to Cpt addition or at various times after Cpt-
washout in triplicate as described under Materials and Methods. For each siRNA transfection rates of DNA synthesis were normalized and expressed 
as a percent of [3H]-thymidine incorporation rates immediately prior to Cpt treatment. each data point represents a mean of triplicate determinations. 
(C and D) In parallel with the experiment described in (B) above A549 cells transfected with siRad18, siFANCD2 or siCon were plated in 10 cm culture 
dishes in replicate. the resulting cultures were treated with 500 nM Cpt for 1 hr (or were left untreated for controls). Cells were harvested immediately 
after 1 hr of Cpt addition or at various times after Cpt washout. extracts were separated to give chromatin and soluble fractions and these were ana-
lyzed by SDS-pAGe and immunoblotting with the indicated antibodies. Note that (C and D) show the results of immunoblots using extracts from the 
same experiment. In (D) extracts from the 1 hr Cpt washout time point were omitted.
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Rad51, whereas Rnf8 depletion was more inhibitory for Rad51 
chromatin loading than for FANCD2 monoubiquitination. It 
is possible, therefore, that additional Rnf8-independent mecha-
nisms contribute to Rad18-mediated FANCD2 ubiquitination. 
In responses to bulky DNA lesions, recruitment of Rad18 to 
stalled replication forks and the ensuing PCNA ubiquitination 
is dependent on RPA-coated ssDNA.53,59 Top1ccs likely gener-
ate RPA-coated ssDNA via resection of replication-dependent 
DSB and at sites of discontinuous DNA replication on the lag-
ging strand.9 Indeed, CPT rapidly induces Chk1 phosphoryla-
tion, a signal that is thought to be initiated by recruitment of 
the ATRIP/ATR complex to RPA-coated ssDNA.60 Thus, it is 
possible that RPA-coated ssDNA contributes to Rad18 activation 
at Top1cc-induced DSB.
Potentially, Rad18 might promote CPT-induced FANCD2 
monoubiquitination activation via inhibition of FANCD2 de-
ubiquitination or by stimulation of FANCD2-directed E3 Ligase 
activity. USP1 is a deubiquitinating enzyme for FANCD2, and 
DNA damage-induced USP1 cleavage has been proposed as a 
major mechanism for increasing levels of monoubiquitinated 
FANCD2 following genotoxin treatments.54,61
We show here that Rad18 status does not affect levels of USP1 
basally or in CPT-treated cells (Fig. 7). Thus, Rad18 is unlikely 
to contribute to CPT-induced FA pathway activation via changes 
in USP1 expression levels. We cannot exclude the possibility that 
Rad18 affects USP1 activity or that Rad18 influences alternative 
(putative) FANCD2-directed DUBs. However, since Rad18-
depletion reduces the chromatin loading of FA core complex pro-
teins, we consider it most likely that Rad18 contributes to FA 
pathway activation by promoting FA core complex activation. 
Precisely how Rad18 E3 ligase activity regulates core complex 
occurs secondary to Rad18-induced PCNA monoubiqui-
tination.27 However, in contrast with bulky DNA lesions, 
CPT does not induce detectable PCNA monoubiquitina-
tion as shown in this study and Niimi et al. Moreover, while 
PCNA monoubiquitination at K164 is important for toler-
ance of UV- or MMS-induced DNA damage, this PCNA 
modification does not contribute to CPT-tolerance.44 Thus, 
Rad18-mediated pathways for repair of Top1cc-induced 
DSB and bulky DNA lesions are separable based on their 
differential requirements for PCNA monoubiquitination.
Previous work by the Chen lab also implicated Rad18 
in tolerance of CPT- and IR-induced DSB.23 Those elegant 
studies identified a novel E3 ligase-independent mechanism 
for Rad18-dependent stimulation of HR, most likely facili-
tated via direct interactions between Rad18 and a Rad51 
paralog, Rad51C.23 Our report identifies an additional 
mechanism for Rad18-dependent FANCD2 ubiquitination 
and tolerance of CPT-induced lesions that is dissociable 
from the pathway described by the Chen lab23 based on its 
requirement for Rad18 E3 ligase activity.
Collectively, these studies indicate that Rad18 plays E3 
ligase-dependent as well as E3 ligase-independent roles in 
tolerance of both bulky DNA lesions (including BPDE 
adducts, CPD and cis-platin) and DSB (Fig. 8). Our study 
reveals an interesting analogy between responses to bulky 
adducts and DSB, whereby Rad18 contributes to tolerance of 
both forms of damage via separable E3 ligase-dependent and 
-independent mechanisms: during TLS Rad18 functions as a 
molecular chaperone that guides Polη to sites of replication fork 
stalling independently of its E3 ligase activity21,58 and subse-
quently monoubiquitinates PCNA to promote stable association 
of TLS polymerases with the replication machinery.19 In response 
to CPT-induced DSB, Rad18 associates with Rad51C and facili-
tates its chromatin loading in an E3 ligase-independent manner23 
yet also promotes FANCD2 ubiquitination, DNA repair and sur-
vival in an E3 ligase-dependent manner (this study).
Our work prompts further questions regarding the mechanism 
of Rad18 activation at Top1ccs-induced DSB and cellular targets 
of Rad18 E3 ligase activity that mediate FA pathway activation. 
Huang et al. showed that RNF8, an E3 ubiquitin ligase involved 
in Histone H2A ubiquitination is required for efficient recruit-
ment of Rad18 to DSB.23 In our study, Rnf8-depletion reduced 
the magnitude of CPT-induced FANCD2 ubiquitination, poten-
tially consistent with a linear activation pathway involving Rnf8, 
Rad18 and FANCD2. We typically observed a slight reduction 
of Rnf8 chromatin loading in Rad18-depleted cells (for example 
see Fig. 5). Chen and colleagues have reported that Rad18 is 
downstream of RNF8 under certain conditions.23 Our experi-
ments may indicate that Rnf8 and Rad18 do not always operate 
in a simple linear pathway. This is by no means unprecedented, 
and participants of DSB signaling pathways do not always have 
simple upstream/downstream relationships. For example, p95 
and ATM have a complex relationship, whereby p95 has roles 
both upstream and downstream of ATM.
Interestingly, Rad18 deficiency had a greater inhibitory effect 
on FANCD2 ubiquitination than on chromatin loading of 
Figure 5. RNF8 mediates FA pathway activation by Cpt. Replicate cultures of 
H1299 cells were transfected with siRad18 and siRnf8 (or non-targeting siCon 
oligonucleotides). the resulting cells were treated with 100 nM Cpt for 1 hr. 
the resulting cells were separated to give soluble and chromatin fractions 
that were analyzed by SDS-pAGe and immunoblotting with the indicated 
antibodies.
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noticed any effects of Rad18 status on electrophoretic 
mobility of UBE2T or FA core complex members that 
we have examined. Nevertheless, it is conceivable that 
reduced ubiquitination of FA core complex proteins in 
Rad18-deficient cells compromises core complex func-
tion. An alternative possibility is that Rad18-mediated 
modification of other replication fork or DNA damage 
signaling components in CPT-treated cells contributes 
to recruitment of the FA core complex. While Rad18 
is most commonly studied in the context of PCNA 
ubiquitination, alternative Rad18 substrates have been 
described, including RFC2 and 53BP1.25,63 Therefore, 
it possible that ubiquitinated forms of RFC2, 53BP1 or 
other unidentified Rad18 targets mediates activation of 
the FA core complex in response to CPT. Regardless 
of the precise mechanism(s) by which Rad18 promotes 
FA pathway activation, this report expands the reper-
toire of DNA repair mechanisms that are known to 
be regulated by Rad18 and reveals a new pathway that 
protects cells from Top1-inhibiting anticancer drugs. 
Further studies are underway to identify additional 
substrates of Rad18 that mediate FA pathway activa-
tion in response to CPT.
Materials and Methods
Cell culture. H1299, A549 and HDF cells were maintained as 
described previously in reference 27. FANCD2-deficient PD20 
cells, FANCA-deficient GM6914 and isogenic cell lines stably 
expressing reconstituted wild-type FANCs were obtained from Dr. 
Alan D’Andrea, Dana Farber Cancer Institute and were validated 
activation remains unclear. The most direct potential mechanism 
for Rad18-dependent FA core complex activation involves ubiq-
uitination of one or more members of the core complex. There is 
a precedent for monoubiquitination of core complex members: 
Dutta and colleagues demonstrated that UBE2T, an E2 ubiquitin-
conjugating enzyme that mediates FANCD2 ubiquitination, is 
itself monoubiquitinated, although this modification is inhibitory 
for E2 ligase activity.62 In preliminary experiments, we have not 
Figure 6. Cpt-induced FA pathway activation does not 
involve pCNA monoubiquitination but requires Rad18 e3 
ligase activity. (A) H1299 cells were serially transfected with 
siRNAs targeting the 3’-UtR region of Rad18 (or with non-
targeting siCon oligonucleotides) and then with pcDNA-
based expression vectors encoding wild-type Rad18, an 
e3 ligase defective Rad18-C28F mutant or “empty” pcDNA 
plasmid for control. Replicate cultures of the resulting cells 
were treated with 100 nM Cpt (or with DMSo for control) 
for 1 hr. Cell extracts were then separated into soluble and 
chromatin fractions, which were analyzed by SDS-pAGe 
and immunoblotting with the indicated antibodies. (B) In 
parallel with the experiment described in (A), H1299 cells 
were depleted of endogenous Rad18, complemented with 
expression plasmids encoding wild-type Rad18, Rad18-C28F 
mutant or with “empty” pcDNA vector for control and then 
tested for Cpt-sensitivity using clonogenic survival assays as 
described under the legend for Figure 1H and Materials and 
Methods. the graph shows the result of a representative ex-
periment. each data point represents the mean of triplicate 
determinations and the error bars represent standard devia-
tions. (C) Replicate plates of H1299 cells were transfected 
with siRad18 or siCon oligonucleotides. the resulting cul-
tures were treated with 100 nM Cpt or were exposed to 20 J/
m2 UVC (or were left untreated for controls). After 2 hr, cells 
were separated into soluble and chromatin fractions, which 
were analyzed by SDS-pAGe and immunoblotting with the 
indicated antibodies.
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with PBS and the resulting membranes were probed with appro-
priate antibodies. Bound antibodies were detected using chemi-
luminiscence. Actin (present in soluble and chromatin fractions 
prepared by this method) was generally used as a loading control. 
Films were scanned, and relative intensities of protein bands were 
determined densitometry using Image J software.
In vivo complex of enzyme (ICE) assay. To assess the forma-
tion of Top1ccs in vivo, exponentially growing cells in 60 mm 
dishes were treated with 1 μM CPT for 30 min and lysed in TE 
buffer (10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) containing 
1% sarkosyl. The cell lysates were fractionated by centrifugation 
in a CsCl gradient for 22 hr as described previously in reference 
68 and 69. For each sample equal volumes of DNA-containing 
fractions were diluted in 25 mM sodium phosphate buffer and 
loaded on to a pre-soaked nitrocellulose membrane using a dot-
blot apparatus (Bio-Rad). The membranes containing immobi-
lized genomic DNA were immunoblotted with Top1 antibody.
Fluorescence microscopy. Exponentially growing cells 
were transfected with indicated siRNAs and plasmid vectors. 
Transfected cells were trypsinized and seeded in two- or four-well 
LabTek chamber slides to give a confluence of 40–60% 16–24 
hours after replating. The resulting cells were treated with CPT 
(or DMSO for controls). At various times after CPT treatment, 
cells were washed with cold PBS and permeabilized with PBS con-
taining 0.2% Triton X-100 (PBS-T) for ~1 min and then washed 
twice with PBS. Permeabilized cells were fixed in 3% formal-
dehyde for 10 min and then in 100% methanol (-20°C) for 10 
min at room temperature. Fixed cells were blocked in 10% FBS 
for 30 min. After three washes with PBS-T, cells were incubated 
overnight at 4°C with primary antibodies in PBS containing 5% 
bovine serum albumin (BSA) and 0.1% Triton X-100 (PBST). 
The slides were washed three times with PBST containing 
1% BSA then incubated with anti-mouse IgG-Cy3 antibodies 
(Sigma-Aldrich) for 2 hr at RT. After washing extensively with 
PBST to remove unbound secondary antibody, the slides were 
for FANC status by immunoblotting as described in recent 
publications.45,64,65 All cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum, streptomycin sulfate (100 μg/ml) and 
penicillin (100 U/ml), 5 mM L-glutamine, and cultures were 
incubated at 37°C in humidified chambers with 5% CO
2
.
Antibodies and drugs. Top1 antibody (Abcam); PCNA; 
Rad51; FANCD2; FANCL; Rnf8; β-actin (Santa Cruz) 
Rad18; (Bethyle); Rad6; γH2AX; p-Chk1; p-Chk2; p-ATM 
(Cell Signaling). Camptothecin (Sigma, St. Louis, MO) was 
dissolved in anhydrous DMSO at 10 mM concentration and 
stored at -20°C. The 10 mM CPT stock solution was diluted 
further in to anhydrous DMSO and added to the cells. All 
other reagents used in this study were analytical grade and 
obtained from certified vendors.
RNA interference (RNAi). All siRNAs used in this 
study were purchased from Dharmacon (Lafayette, CO) and 
transfected using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocols as described previously 
in reference 27 and 58. The siRNAs used in this study are as 
follows: siRad18-3, 5'-GAG CAU GGA UUA UCU AUU 
CAA UU-3', previously described by Hicks et al. siRad18-3'UTR, 
5'-UUA UAA AUG CCC AAG GAA AUU-3'; siFANCD2, 
5'-GCA CCG UAU UCA AGU ACA AUU-3'; siFANCA, 
5'-CAG CGT TGA GAT ATC AAA GAT-3'; siFANCI, 5'-CTG 
GCT AAT CAC CAA GCT TAA-3'; siRNF8, 5'-GAG AAG 
CUU ACA GAU GUU U-3'; non-targeting siControl, 5'-UAG 
CGA CUA AAC ACA UCA AUU-3'. For all knockdowns, cells 
were transfected twice (8–10 hr for each transfection) using 100–
150 nM siRNA with a 24 hour recovery period between the first 
and second transfections. Cells were typically subjected to geno-
toxin treatments 24 hr after the second transfection.
SDS-PAGE and immunoblotting. Cells were harvested by 
aspirating the medium and washing twice with cold phosphate 
buffer saline (PBS). Chromatin (essentially nucleated cytoskel-
etons) and soluble fractions were prepared according to standard 
protocols essentially as described by Izumi and colleagues.67 
Briefly, cells were resuspended in cytoskeleton (CSK) buffer 
(10 mM PIPES (pH 6.8), 100 mM NaCl, 300 mM sucrose, 
3 mM MgCl
2





, 10 mM NaF and 0.1% Triton X-100, freshly 
supplemented with protease inhibitor and phos-stop cocktail 
tablets from Roche), scraped into microfuge tubes and allowed 
to lyse for 10–20 min on ice. Detergent-insoluble nuclei and 
soluble fractions were separated by centrifugation at 3,000 g 
for 5 min. The soluble fractions were removed, and the remain-
ing insoluble nuclear pellets were washed twice with 0.5 ml of 
lysis buffer. The resulting washed nuclei were resuspended in 
an approximately equal volume of CSK. Protein concentrations 
of soluble and nuclear fractions were determined immediately. 
Extracts were normalized for protein content, dissolved in 4x 
SDS-PAGE denaturing buffer and heated to 100°C for 10 min. 
Denatured samples were resolved by SDS-PAGE and transferred 
to nitrocellulose membranes. Membranes were typically stained 
with Ponceau to verify transfer and equivalent loading protein 
loading. Used as Ponceau stain was removed by extensive rinsing 
Figure 7. USp1 expression levels are insensitive to Cpt and Rad18. Repli-
cate plates of H1299 cells were transfected with siRad18, siUSp1 or siCon 
oligonucleotides. the resulting cultures were treated with 100 nM Cpt. After 
2 hr, cells were separated into soluble and chromatin fractions, which were 
analyzed by SDS-pAGe and immunoblotting with the indicated antibodies.
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Reproducibility. All data shown are representative of experi-
ments that were performed at least three times with qualitatively 
similar results on each occasion.
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mounted with DAPI-containing VECTASHIELD® Mounting 
Medium (Vector Laboratories) and imaged and analyzed with an 
Olympus BX61 upright fluorescence microscope using a U Plan 
Fluorite Apo 40x objective lens.
Survival assays. H1299 or A549 cells were transfected with 
indicated siRNAs and plasmid vectors. 48 hours post-transfec-
tion, 300–500 cells were plated in triplicate in six-well tissue cul-
ture dishes. Cells were allowed to attach for 16 hours and treated 
with indicated concentrations of CPT for 16–20 h. Following 
CPT treatment, cells were washed three times with PBS, once 
with (CPT-free) growth medium and placed in fresh complete 
medium. After 7–10 days, surviving colonies were fixed with 
methanol for 10 min and stained with crystal violet. Colonies 
containing at least 50 cells were enumerated.
Figure 8. e3 ubiquitin ligase-dependent and e3 ligase-independent roles of Rad18 in tolerance of bulky DNA lesions (left) and replication-associated 
DSB (right). In response to bulky lesions such as UV-induced CpD, Rad18 associates with and chaperones polη to sites of replication stalling in an e3 
ligase-independent manner. At the stalled replication fork Rad18 monoubiquitinates pCNA facilitating stable engagement of tLS polymerases with 
the DNA replication machinery, enabling lesion bypass and DNA damage tolerance. In response to replication-induced DSB, Rad18 associates with 
Rad51C and facilitates HR in an e3 ligase-independent manner, as demonstrated by Huang et al. Additionally, DSB-induced FA pathway activation and 
DNA damage tolerance requires Rad18 e3 ligase activity (this study).
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